down

A development stage biopharmaceutical company that develops a fibrin-derived peptide for the treatment of diseases related to vascular leakage
e.g., ARDS in patients with underlying COVID-19 infection.

More soon...

down

Press releases

Wellington invests in SIRS Therapeutics

Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications

down
SIRS Therapeutics GmbH
Türkenstraße 5
80333 München
Handelsregister: München 240453
VAT-ID: DE331612834

Kontakt: info@sirs-therapeutics.com